Sourcing comparison · Pharmaceutical Ingredients (API)
Tariff & fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
| Annual import value | Estimated duty & fee savings / year |
|---|---|
| $50,000 | $2,374 |
| $250,000 | $11,869 |
| $1,000,000 | $47,475 |
Savings scale linearly with volume. Enter your exact figure to model it precisely.
Calculate your exact volume →Few procurement levers move landed cost on pharmaceutical ingredients (api) as fast as switching country of origin. Switch the origin from China (14.5%) to Taiwan (10%) and an importer reclaims about $4,748 for every $100,000 purchased. Unlike freight or FX, the duty rate is set by which country's stamp the goods carry — a choice made at the contract, not at the port. What follows is the layer-by-layer comparison, the trade context behind each rate, and how the gap grows with volume.
Start with the two duty stacks side by side. Sourced from China, the goods face a 2% Most-Favoured-Nation base duty and a 12.5% forced-labor Section 301 duty on its pharmaceutical ingredients (api), an effective 14.5% once the $49.74 in processing fees are added. Taiwan-made goods carry a 2% Most-Favoured-Nation base duty and an 8% forced-labor Section 301 duty on its pharmaceutical ingredients (api), an effective 10% once the $49.74 in processing fees are added. The Merchandise Processing Fee and Harbor Maintenance Fee are charged on customs value, not origin, so they sit at $49.74 on either stack and never contribute to the gap. That leaves a $474.75 gap on every $10,000 of goods, driven entirely by the 4.5% spread in effective duty rate. That same per-dollar gap is about $1,187 on a $25,000 order and $4,748 on $100,000 of annual volume. Scaled to a single $25,000 PO, the gap is near $1,187, repeated on every reorder.
Classified in HTS chapter 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, pharmaceutical ingredients (api) spans products like Antibiotic APIs, Analgesic APIs, Cardiovascular APIs, Oncology ingredients, Vitamin synthesis intermediates, Steroid hormones, and Insulin precursors. For pharmaceutical ingredients (api), where buyers reorder frequently, the duty rate compounds into one of the largest controllable costs on the P&L. On carve-outs: pharmaceutical ingredients carried a Section 122 carve-out before the surcharge lapsed to 0% sitewide on July 24, 2026, so it no longer adds anything regardless of origin. Also exempt from Section 301. Section 232 (Proclamation 11020) treats this category as a MIXED BASKET, and the dividing line is patent status, not HTS chapter. Generic active pharmaceutical ingredients and key starting materials are expressly outside the action. Active pharmaceutical ingredients and key starting materials for PATENTED products — those listed in the FDA Orange Book or Purple Book — are in scope at up to 100 percent ad valorem, subject to company- and country-specific reductions (20 percent approved-onshoring, 15 percent Japan/EU/Korea/Switzerland-Liechtenstein, 10 percent United Kingdom). This calculator does not distinguish patent status and therefore adds no Section 232 duty here; verify a specific article against HTSUS headings 9903.04.60-9903.04.69. Standard MFN rates apply. China, in Asia-Pacific, ships the US mainly consumer electronics, computers servers, and clothing garments. China trades without a special US agreement, so column-1 rates and every surcharge apply to its pharmaceutical ingredients (api) in full. Taiwan (Asia-Pacific) sends the United States largely semiconductors chips, computers servers, and consumer electronics. Taiwan trades under a bilateral arrangement that sets a fixed rate on pharmaceutical ingredients (api) alongside the standard duty layers. Shared Asia-Pacific routing keeps logistics roughly comparable and leaves the duty gap as the decisive number. Taiwan is surfaced as a credible alternative, not just the cheapest line — it is among the origins a US buyer of pharmaceutical ingredients (api) could realistically qualify. Sourcing diversification has shifted from resilience theatre to margin necessity, and a documented second source like Taiwan is how buyers act on it.
Where Taiwan is a viable supplier, expect roughly $4,748 at $100,000, rising to about $11,869 at $250,000 and $47,475 at $1,000,000 as volume grows. The numbers come straight from the landed-cost engine, with product cost and shipping fixed across both origins to isolate the tariff difference. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier. If any price premium from Taiwan is smaller than the duty saving, the switch still wins on net landed cost. Before acting, confirm the Taiwan supplier classifies under the same HTS heading, can meet your volume and certifications, and faces no product-specific exclusion or quota that shifts the duty. Lock the comparison to a quote date; a surcharge added or lifted can change the ranking between negotiation and purchase order. Open the Tariff Savings Finder to rank every feasible origin for your specific volume.
At $100,000 of annual import value, switching from China to Taiwan saves an estimated $4,748 in duties and fees, because the effective tariff rate falls from 14.5% to 10%. The saving scales linearly with volume. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
Taiwan-origin pharmaceutical ingredients (api) is assessed a 2% Most-Favoured-Nation base duty and an 8% forced-labor Section 301 duty, for an effective 10% duty rate before the Merchandise Processing Fee ($36.55) and Harbor Maintenance Fee ($13.19).
China carries an effective 14.5% rate versus 10% for Taiwan. The gap comes from differences in the base, Section 232 and bilateral rates that apply to each origin.
Tariff rates from Tax Foundation, USITC, and Penn Wharton Budget Model; retaliatory and industry data from the ITA Foreign Retaliations Database and U.S. Census Bureau (NAICS). Last verified .
